{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+2&page=2", "query": { "condition": "Parkinson Disease 2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T15:17:11.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05357989", "title": "A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease, Idiopathic" ], "interventions": [ { "name": "buntanetap/posiphen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annovis Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 523, "start_date": "2022-08-03", "completion_date": "2023-12-04", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05357989" }, { "nct_id": "NCT04658186", "title": "A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-stage Parkinson's Disease" ], "interventions": [ { "name": "UCB0599", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 496, "start_date": "2020-12-30", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04658186" }, { "nct_id": "NCT04700072", "title": "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 56, "start_date": "2021-05-03", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 9, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04700072" }, { "nct_id": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-08-07", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445972" }, { "nct_id": "NCT05557864", "title": "Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Deep Brain Stimulation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "21 Years to 89 Years" }, "enrollment_count": 24, "start_date": "2016-08-25", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557864" }, { "nct_id": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan (sac-TMT)", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Patritumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2024-09-20", "completion_date": "2029-09-12", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06469944" }, { "nct_id": "NCT05950906", "title": "Study to Assess PDM608 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "PDM608", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calibr, a division of Scripps Research", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2023-06-27", "completion_date": "2024-04-19", "has_results": true, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950906" }, { "nct_id": "NCT03234478", "title": "Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Parkinson", "Parkinson Disease", "Genetic Predisposition", "GBA Gene Mutation", "Cognitive Decline" ], "interventions": [ { "name": "cognitive assessments", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 150, "start_date": "2017-07-01", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234478" }, { "nct_id": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)", "Gastroesophageal Junction Carcinoma (GEJC)", "Esophageal Adenocarcinoma (EAC)" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2020-02-28", "completion_date": "2026-06-26", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 19, "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210115" }, { "nct_id": "NCT04334317", "title": "A Study of TAK-071 in People With Parkinson Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson Disease", "Healthy Participants" ], "interventions": [ { "name": "TAK-071", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 64, "start_date": "2020-10-21", "completion_date": "2023-02-27", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-06-10T15:17:11.300Z", "location_count": 21, "location_summary": "Garden Grove, California • Irvine, California • Los Angeles, California + 18 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334317" } ] }